Relapsing-remitting multiple sclerosis

This study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…

This study tested an extra dose of the HIPRA COVID-19 vaccine in 241 adults with conditions like HIV, kidney disease, or autoimmune disorders that weaken the immune system. The goal was to see if the booster raises antibody levels against virus variants and remains safe. Research…

This early-phase trial tested a new treatment for relapsing-remitting multiple sclerosis (RRMS) that uses a patient's own red blood cells. The cells are coated with specific peptides and given back to the patient to teach the immune system to stop attacking the body. The study in…

This completed Phase 3 trial tested the oral drug dimethyl fumarate (Tecfidera) against an injected interferon in 156 children aged 10 to 17 with relapsing-remitting multiple sclerosis. The main goal was to see if the drug could prevent new brain lesions and control the disease s…

This study tested a treatment called extracorporeal photopheresis (ECP) in 15 people with multiple sclerosis. ECP is a procedure that filters a person's blood, treats it with light, and returns it to the body. The goal was to see if it is safe and if it can improve walking, hand …

This study looked at whether it is safe for people with multiple sclerosis to receive their natalizumab (Tysabri) infusions at home instead of at a hospital. Researchers compared serious side effects, quality of life, and costs over one year in 295 patients. The goal was to see i…

This study followed 107 adults in Switzerland with relapsing multiple sclerosis who were already taking Kesimpta (ofatumumab) as part of their routine care. Researchers tracked how many patients had no signs of disease activity, including relapses, new brain lesions, or worsening…

This early-phase trial tested a new drug called VIS171 in 61 people: first in healthy volunteers, then in patients with autoimmune diseases. The main goal was to check safety and how the body processes the drug. No results on whether it actually helps the disease are available ye…

This study looked at how well ofatumumab works in 562 people with relapsing multiple sclerosis who switched from other drugs (fumarates or fingolimod) because their disease was still active. The main goal was to see how many relapses they had per year. Researchers also tracked si…

This Phase 3 study tested whether ofatumumab, a monthly injection, works better than standard first-line disease-modifying therapies (like glatiramer acetate or interferon) in people newly diagnosed with relapsing multiple sclerosis. The main goal was to see if more patients coul…

This study tested a monthly injection of ofatumumab in 180 people with very early relapsing-remitting multiple sclerosis (MS). The goal was to see if the drug could stop all signs of disease activity—like relapses, disability worsening, and new brain lesions—over 18 months. Resea…

This study tested an experimental drug called BIIB091, alone or combined with an approved MS drug (diroximel fumarate), in 127 people with relapsing multiple sclerosis. The goal was to check safety and see if it reduces brain inflammation on MRI scans. Participants took pills twi…

This study followed 1,710 people with relapsing or primary progressive multiple sclerosis who were prescribed ocrelizumab (Ocrevus) as part of their normal care. Researchers tracked symptoms like fatigue, mobility, and cognition, as well as side effects, to see how well the drug …

This study looked at how well ocrelizumab works in Black and Hispanic patients with relapsing multiple sclerosis (MS). About 179 participants received the drug and were monitored for relapses, disability progression, and brain lesions over 48 weeks. The goal was to see if the tre…

This study looked at whether people with relapsing multiple sclerosis can safely switch from an intravenous (IV) anti-CD20 antibody treatment to a self-injected drug called ofatumumab. 111 adults took part, and researchers tracked their brain scans and side effects for a year. Th…

This study looked at how well and how safely the drug fingolimod (Gilenya) works for people in China with relapsing multiple sclerosis (RMS), a condition where the immune system attacks the nerves. Over 24 months, 98 participants took a daily 0.5 mg pill. The main goal was to see…

This study tested the drug ofatumumab in 99 Chinese adults with relapsing multiple sclerosis (RMS). The goal was to see if monthly injections could reduce the number of relapses and monitor for side effects. Participants received the drug for 12 months, and researchers tracked re…

This completed study looked at how well cladribine tablets work in everyday practice for people with relapsing multiple sclerosis (MS) who had a poor response to other oral or infusion treatments. Researchers tracked 291 participants over 24 months, measuring relapse rates and pa…

This study looked at how ocrelizumab, a standard MS medication, changes brain inflammation in 22 people with multiple sclerosis. Researchers used special PET and MRI scans to measure inflammation before and after one year of treatment. The goal was to see if the drug reduces harm…

This completed study in Spain looked at 310 people with relapsing multiple sclerosis who were taking ofatumumab (Kesimpta®). Researchers wanted to see how well the drug reduced relapses and how safe it was in everyday medical practice. The study collected information from medical…

This phase 2 trial tested a liquid suspension of gold nanocrystals, called CNM-Au8, in 33 people with relapsing multiple sclerosis. The goal was to see if the treatment could improve energy metabolism in brain cells, measured by a special MRI scan. Participants took the drug by m…

This completed Phase 2 trial tested whether combining two common drugs—metformin (for diabetes) and clemastine (an antihistamine)—can help repair the protective lining of nerve cells in people with relapsing-remitting multiple sclerosis. The 70 participants continued their usual …

This phase 3 study tested the safety and tolerability of diroximel fumarate (Vumerity) in 136 East Asian adults with relapsing forms of multiple sclerosis. Participants took the drug for up to 48 weeks, and researchers monitored side effects, lab results, and drug levels in the b…

This study tested an experimental oral drug called PIPE-307 in 182 adults with relapsing-remitting multiple sclerosis (MS). Participants took either a low or high dose of PIPE-307 or a placebo daily for about 30 weeks, alongside their usual MS medication. The goal was to see if t…

This study tested the long-term safety of the drug SAR442168 in 125 people with relapsing multiple sclerosis who had already completed a previous study. Researchers monitored side effects and checked brain scans for disease activity over about 4.5 years. The goal was to see if th…

This study tested whether a person's own stem cells (called HB-adMSCs) could improve quality of life for people with multiple sclerosis. Twenty-four adults with relapsing-remitting MS received either the stem cells or a placebo through six infusions over a year, while continuing …

This phase 2 trial tested clemastine fumarate, a common allergy medicine, to see if it could repair damaged nerves in people with relapsing-remitting multiple sclerosis. Fifty participants took either the drug or a placebo for several months. The study measured nerve signals in t…

This phase 2b trial tested an experimental oral drug called SAR442168 in 130 adults with relapsing multiple sclerosis. The goal was to find the best dose to reduce new active brain lesions seen on MRI scans. Participants took the drug or a placebo for 12 to 16 weeks, and research…

This study followed 450 people with relapsing-remitting multiple sclerosis (RRMS) in Germany who were already prescribed ozanimod (Zeposia). Over three years, researchers collected data on how long patients stayed on the drug, its effect on quality of life, and any side effects. …

This study looked at a device called GLOBAFFIN that filters antibodies from the blood to help people with autoimmune diseases. It involved 34 adults and measured how much harmful antibodies were removed and if patients felt better. The goal was to see if the device is safe and wo…

Researchers tested an artificial intelligence program that analyzes retinal images to diagnose several nerve and brain conditions, such as optic neuropathy and brain tumors. The study used data from 693 patients with confirmed diagnoses. The goal is to create a fast triage tool f…

This trial investigates whether a non-invasive technique called transcranial direct current stimulation (tDCS) can help with fatigue, depression, anxiety, and cognitive problems in people with multiple sclerosis (MS). tDCS uses a weak electrical current applied to the scalp to ge…

This study tests whether adding task-oriented training—like walking on different surfaces, climbing stairs, and reaching for objects—to standard aerobic and strength exercises can improve functional mobility, balance, and fatigue in people with relapsing-remitting multiple sclero…

This study compares two gentle exercise programs—tai chi and square stepping—in women with multiple sclerosis. Researchers want to see if these activities improve knee joint awareness, leg strength, and fatigue. About 39 women aged 20-45 with mild MS will participate, helping to …

This study tested whether adding probiotics (found in yogurt and yeast tablets) to standard therapy could improve fatigue, quality of life, mood, and inflammation in 60 people with relapsing-remitting multiple sclerosis. Participants were randomly assigned to take probiotics or n…

This completed pilot study looked at whether a placebo treatment — sham TENS combined with positive verbal suggestions — could reduce fatigue in people with relapsing-remitting multiple sclerosis. 36 participants were enrolled. The main goal was to measure motor performance (numb…

This study tested whether a home-based program combining motor imagery (mentally practicing movements) and action observation (watching videos of movements) could help people with multiple sclerosis improve balance, walking, and fatigue. Twenty-nine adults with MS participated in…

This study tested whether plasma exchange (a blood-filtering treatment) helps people with multiple sclerosis who have severe flare-ups that don't get better with steroids. Thirty-eight adults took part, and researchers compared real plasma exchange to a sham procedure. The main g…

This study tested whether acupressure, a technique where pressure is applied to specific points on the body, can help people with multiple sclerosis (MS) manage pain, fatigue, and sleep problems. Researchers enrolled 90 adults with relapsing-remitting MS who had moderate to sever…

This study tested whether applying shock wave therapy to the soles of the feet could improve balance and walking in people with multiple sclerosis (MS). Fifty-four participants received the therapy three times a week for six weeks. Researchers measured changes in foot sensation, …

This study tested whether a low-histamine version of the Mediterranean diet could help people with relapsing-remitting multiple sclerosis (MS) feel better. 51 adults were split into three groups: one followed the low-histamine Mediterranean diet, another a standard Mediterranean …

This study looked at whether a diet low in salt and sugar can reduce common side effects of corticosteroid treatment, such as weight gain, high blood pressure, and diabetes. Fifty adults with autoimmune diseases or asthma who were starting high-dose corticosteroids were randomly …

This study compared two ways of delivering exercise programs to people with relapsing-remitting multiple sclerosis: live online sessions with a therapist versus pre-recorded videos. Sixteen participants completed a 12-week program focusing on strength, core stability, and stretch…

This study looked at whether a water-based exercise program (hydrotherapy) could help improve balance and reduce fatigue in people with multiple sclerosis. 26 adults with relapsing-remitting MS took part in 16 hydrotherapy sessions. Researchers measured changes using the Berg Bal…

This study looked at whether two types of talk therapy—cognitive behavioral therapy (CBT) and relaxation training—could improve mood and thinking in people with relapsing-remitting multiple sclerosis. 140 participants with mild to moderate disability were randomly assigned to one…

This study tested whether special leg exercises could improve balance, walking, and fatigue in people with multiple sclerosis (MS). Twenty-six adults with MS did either the special exercises or standard leg strengthening for six weeks. The goal was to see if these exercises could…

This study tested whether personalized dietary advice from a dietitian helps people with multiple sclerosis (MS) get more calcium in their diet. 182 MS patients who could still walk were split into two groups: one received one-on-one dietitian sessions, the other got a standard a…

This study tested whether a combination of mild brain stimulation (tDCS) and computer-based cognitive training could improve memory, attention, and brain flexibility in people with multiple sclerosis. Forty-five adults with relapsing-remitting MS took part. The goal was to see if…

This study looked at whether asking people with multiple sclerosis (MS) to do two things at once — like walking while thinking — can uncover balance problems that standard tests miss. Researchers studied 24 people with mild MS and low disability. The goal was to see if this dual-…

This study looked at 719 people, including patients with autoimmune connective tissue diseases like myositis, their blood relatives, and healthy volunteers. Researchers collected blood samples and medical histories to find genetic and environmental factors that may trigger these …

This study followed 115 people with relapsing-remitting multiple sclerosis for up to 5 years to see if early damage to the spinal cord could predict later walking difficulties. Researchers used MRI scans and walking tests to track changes. The goal was to better understand how ea…

This study used advanced MRI scans to look at energy use in the brains of 40 people with multiple sclerosis and 15 healthy volunteers. The goal was to see if energy problems in brain cells can predict nerve damage over two years. Researchers hope this will help understand how MS …

This study tested whether smartphone communication and a special questionnaire could help confirm MS relapses without requiring an in-person visit. Researchers worked with 150 people with relapsing-remitting MS to see if this approach improves patient satisfaction and care. The g…

This study followed 307 people with relapsing multiple sclerosis in Germany who had recently switched to the drug Kesimpta (ofatumumab) from another treatment. Researchers collected information on why patients made the switch and how many doses they missed over one year. The goal…

This study looked at over 13,000 people with chronic inflammatory rheumatism or autoimmune diseases who had or were suspected to have COVID-19. Researchers tracked how many developed severe COVID-19 requiring intensive care or leading to death. They also examined risk factors lik…

This completed study looked at 75 people with relapsing-remitting multiple sclerosis (RRMS) who were taking the medication Aubagio. The goal was to see if virtual reality tests and real-world tasks could better detect cognitive (thinking) problems in everyday life compared to sta…

This study looked at how nerve cells in the eye are lost in people with multiple sclerosis (MS) even when there is no active inflammation. Researchers followed 64 adults with relapsing-remitting MS who were already part of a larger study. By using special eye scans over time, the…

This study used brain scans to understand why some people with multiple sclerosis have trouble with social thinking, like reading emotions or intentions. Researchers compared 35 MS patients to healthy volunteers using MRI while they performed social tasks. The goal was to see whi…

This study looked at whether a multiple sclerosis (MS) drug called Ofatumumab (Kesimpta) can make immune cells less toxic to brain cells. Researchers took blood samples from 40 people with relapsing-remitting MS before and after 6 months of treatment. They tested if the chemicals…

This study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of dise…

This completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers …

This study tested whether home automation and remote monitoring can help elderly people (65+) with multiple chronic conditions live safely at home. Over 500 participants had their homes equipped with sensors that tracked health signs and sent alerts to doctors. The main goal was …

This study looked at how the COVID-19 pandemic changed the way people with multiple sclerosis (MS) reported and managed their relapses. Researchers compared 51 patients who had a relapse during the first wave of the pandemic (April–June 2020) with those who had a relapse during t…

This study looked at how well people with relapsing multiple sclerosis (RMS) follow their Kesimpta (Ofatumumab) treatment plan. Researchers used data from the MSGo patient support app to track when doses were taken. They also compared how patients felt (reported symptoms) with th…

This completed study involved 15 people with relapsing-remitting multiple sclerosis who were already taking alemtuzumab. Researchers measured anti-drug antibodies in their blood over 24 months to see if these antibodies affect treatment or cause infusion reactions. The goal was t…

This study aimed to translate and validate an Italian version of a tool that helps speech therapists assess swallowing difficulties (dysphagia) in people with neurodegenerative diseases like Parkinson's or ALS. Researchers tested the tool on 101 adults with such conditions to ens…

This study compared traditional pencil-and-paper tests with virtual reality tasks (like driving simulations and a virtual supermarket) to assess attention and executive function in 60 people with relapsing-remitting multiple sclerosis. The goal was to see if VR can better detect …

This completed study looked at how different types of brain damage—from strokes, tumors, infections, or degenerative diseases—affect thinking and memory. Researchers used brain scans (MRI) and cognitive tests in 346 patients and healthy volunteers to map which brain areas are res…

This study followed 10 adults with relapsing multiple sclerosis for 9 months to see how the drug ofatumumab affects microglia, the brain's immune cells. Researchers used special PET scans and blood tests to track changes. The goal was to understand how the drug works in the brain…

This study looked at fatigue in 60 people with multiple sclerosis (MS) to compare how patients describe their tiredness with results from physical and cognitive tests. Researchers used questionnaires, walking tests, grip strength, and balance assessments to get a fuller picture o…

This study looked at 94 people with relapsing-remitting multiple sclerosis to better understand why standard MRI scans often don't match a person's actual walking ability. Researchers used advanced MRI to measure damage in brain and spinal cord pathways important for movement and…

This study compared 101 people with multiple sclerosis to healthy volunteers to see if they can recognize positive emotions like joy and enthusiasm. Participants completed questionnaires and tests to evaluate their ability to identify emotions from faces and voices. The goal was …

This completed survey looked at whether healthcare professionals and people with multiple sclerosis (or their caregivers) understand the safety steps needed when using the drug Mayzent (siponimod). Over 300 participants from Europe answered questions about proper use, side effect…

This completed observational study followed 367 people with relapsing-remitting or active secondary progressive multiple sclerosis who were taking Kesimpta for the first time. Researchers tracked side effects and how well the drug worked in everyday use. The goal was to gather re…

This study reviewed medical records of 800 multiple sclerosis patients to see if gender, race, or socioeconomic status affected how quickly they started Ocrelizumab or how well it worked. Researchers looked at relapse rates and MRI changes over 12 to 24 months. The goal was to id…

This early-phase study tested the safety and tolerability of a new drug called LAD191 in 69 healthy adults and people with an autoimmune disease. Researchers gave single or multiple doses to see how the body processes the drug and if it causes side effects. The goal was to gather…

This study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…

This completed study measured two proteins in the blood—neurofilament light chain and GFAP—that can signal nerve damage. Researchers compared 15 people with atypical MS, 30 with typical MS, and 15 healthy controls to see if these markers differ. The goal was to better understand …

This study looked at 104 people with relapsing-remitting multiple sclerosis (RRMS) who switched their disease-modifying therapy to ozanimod. Researchers tracked why they switched (e.g., lack of effectiveness, side effects) and how the switch was done. The goal was to understand r…

This study looked at how different types of exercise affect the brain and body in people with multiple sclerosis (MS). Twelve participants tried traditional aerobic exercise, virtual reality (VR) aerobic exercise (using the game Beat Saber), and standard exercises. Researchers me…

This completed study looked at how depression affects the ability to recognize emotions in people with multiple sclerosis (MS). Researchers used EEG, heart rate monitoring, and questionnaires to compare emotion recognition in MS patients with and without depression, as well as he…